New drug called Dapagliflozin available for heart failure patients

9th September 2019

For heart failure patients there could soon be another new drug available alongside Entresto, called Dapagliflozin.

This new drug will help people not only live longer and avoid hospitalisation but more importantly feel better within themselves.

Dapagliflozin is typically used to treat people with type 2 diabetes; however the most recent DAPA-HF study has shown substantial benefits for people with heart failure. For most people this will be prescribed in addition to their usual medications as it is an entirely new type of drug. Professor John McMurray MD University of Glasgow said, “It (Dapagliflozin) did all of the things we would like any drug to do in heart failure … improve symptoms, reduce hospital admissions and increase survival.” Further studies are underway to assess the drug’s usefulness for people with heart failure symptoms with a normal heart function.

Jayne Partridge Cardiomyopathy UK support nurse said, “This is indeed an exciting time for the treatment of people diagnosed with heart failure, a new medication which works with established heart failure treatments has been found to help prevent heart failure patients needing to go into hospital and more importantly help them ‘feel ‘ better. Quality of life is so vitally important for people diagnosed with a heart condition and shouldn’t be underestimated, this new medication could be the start of a big change in available treatments for heart failure patients in the near future.”

Cardiomyopathy UK will be following the progress of this new medication and will update our community as soon as we know more from the results of ongoing research in the DELIVER and DETERMINE trials and will be interested in findings when this drug is licenced for prescription for heart failure patients in the UK.